Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia

Rong Chen, Mingzhao Zhu, Rajan R. Chaudhari, Omar Robles, Yuling Chen, Wesley Skillern, Qun Qin, William G. Wierda, Shuxing Zhang, Kenneth G. Hull, Daniel Romo, William Plunkett

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The viability of chronic lymphocytic leukemia (CLL) is critically dependent upon staving off death by apoptosis, a hallmark of CLL pathophysiology. The recognition that Mcl-1, a major component of the anti-apoptotic response, is intrinsically short-lived and must be continually resynthesized suggested a novel therapeutic approach. Pateamine A (PatA), a macrolide marine natural product, inhibits cap-dependent translation by binding to the initiation factor eIF4A. In this study, we demonstrated that a synthetic derivative of PatA, des-methyl des-amino PatA (DMDAPatA), blocked mRNA translation, reduced Mcl-1 protein and initiated apoptosis in CLL cells. This action was synergistic with the Bcl-2 antagonist ABT-199. However, avid binding to human plasma proteins limited DMDAPatA potency, precluding further development. To address this, we synthesized a new series of PatA analogs and identified three new leads with potent inhibition of translation. They exhibited less plasma protein binding and increased cytotoxic potency toward CLL cells than DMDAPatA, with greater selectivity towards CLL cells over normal lymphocytes. Computer modeling analysis correlated their structure–activity relationships and suggested that these compounds may act by stabilizing the closed conformation of eIF4A. Thus, these novel PatA analogs hold promise for application to cancers within the appropriate biological context, such as CLL.

Original languageEnglish (US)
Pages (from-to)1663-1674
Number of pages12
JournalLeukemia
Volume33
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Survival
Proteins
Blood Proteins
Apoptosis
Peptide Initiation Factors
Macrolides
Protein Biosynthesis
Biological Products
Protein Binding
Lymphocytes
pateamine A
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. / Chen, Rong; Zhu, Mingzhao; Chaudhari, Rajan R.; Robles, Omar; Chen, Yuling; Skillern, Wesley; Qin, Qun; Wierda, William G.; Zhang, Shuxing; Hull, Kenneth G.; Romo, Daniel; Plunkett, William.

In: Leukemia, Vol. 33, No. 7, 01.07.2019, p. 1663-1674.

Research output: Contribution to journalArticle

Chen, Rong ; Zhu, Mingzhao ; Chaudhari, Rajan R. ; Robles, Omar ; Chen, Yuling ; Skillern, Wesley ; Qin, Qun ; Wierda, William G. ; Zhang, Shuxing ; Hull, Kenneth G. ; Romo, Daniel ; Plunkett, William. / Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. In: Leukemia. 2019 ; Vol. 33, No. 7. pp. 1663-1674.
@article{c50cc9a2da8e4ff1b3e4cf6a36bb9385,
title = "Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia",
abstract = "The viability of chronic lymphocytic leukemia (CLL) is critically dependent upon staving off death by apoptosis, a hallmark of CLL pathophysiology. The recognition that Mcl-1, a major component of the anti-apoptotic response, is intrinsically short-lived and must be continually resynthesized suggested a novel therapeutic approach. Pateamine A (PatA), a macrolide marine natural product, inhibits cap-dependent translation by binding to the initiation factor eIF4A. In this study, we demonstrated that a synthetic derivative of PatA, des-methyl des-amino PatA (DMDAPatA), blocked mRNA translation, reduced Mcl-1 protein and initiated apoptosis in CLL cells. This action was synergistic with the Bcl-2 antagonist ABT-199. However, avid binding to human plasma proteins limited DMDAPatA potency, precluding further development. To address this, we synthesized a new series of PatA analogs and identified three new leads with potent inhibition of translation. They exhibited less plasma protein binding and increased cytotoxic potency toward CLL cells than DMDAPatA, with greater selectivity towards CLL cells over normal lymphocytes. Computer modeling analysis correlated their structure–activity relationships and suggested that these compounds may act by stabilizing the closed conformation of eIF4A. Thus, these novel PatA analogs hold promise for application to cancers within the appropriate biological context, such as CLL.",
author = "Rong Chen and Mingzhao Zhu and Chaudhari, {Rajan R.} and Omar Robles and Yuling Chen and Wesley Skillern and Qun Qin and Wierda, {William G.} and Shuxing Zhang and Hull, {Kenneth G.} and Daniel Romo and William Plunkett",
year = "2019",
month = "7",
day = "1",
doi = "10.1038/s41375-018-0364-x",
language = "English (US)",
volume = "33",
pages = "1663--1674",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia

AU - Chen, Rong

AU - Zhu, Mingzhao

AU - Chaudhari, Rajan R.

AU - Robles, Omar

AU - Chen, Yuling

AU - Skillern, Wesley

AU - Qin, Qun

AU - Wierda, William G.

AU - Zhang, Shuxing

AU - Hull, Kenneth G.

AU - Romo, Daniel

AU - Plunkett, William

PY - 2019/7/1

Y1 - 2019/7/1

N2 - The viability of chronic lymphocytic leukemia (CLL) is critically dependent upon staving off death by apoptosis, a hallmark of CLL pathophysiology. The recognition that Mcl-1, a major component of the anti-apoptotic response, is intrinsically short-lived and must be continually resynthesized suggested a novel therapeutic approach. Pateamine A (PatA), a macrolide marine natural product, inhibits cap-dependent translation by binding to the initiation factor eIF4A. In this study, we demonstrated that a synthetic derivative of PatA, des-methyl des-amino PatA (DMDAPatA), blocked mRNA translation, reduced Mcl-1 protein and initiated apoptosis in CLL cells. This action was synergistic with the Bcl-2 antagonist ABT-199. However, avid binding to human plasma proteins limited DMDAPatA potency, precluding further development. To address this, we synthesized a new series of PatA analogs and identified three new leads with potent inhibition of translation. They exhibited less plasma protein binding and increased cytotoxic potency toward CLL cells than DMDAPatA, with greater selectivity towards CLL cells over normal lymphocytes. Computer modeling analysis correlated their structure–activity relationships and suggested that these compounds may act by stabilizing the closed conformation of eIF4A. Thus, these novel PatA analogs hold promise for application to cancers within the appropriate biological context, such as CLL.

AB - The viability of chronic lymphocytic leukemia (CLL) is critically dependent upon staving off death by apoptosis, a hallmark of CLL pathophysiology. The recognition that Mcl-1, a major component of the anti-apoptotic response, is intrinsically short-lived and must be continually resynthesized suggested a novel therapeutic approach. Pateamine A (PatA), a macrolide marine natural product, inhibits cap-dependent translation by binding to the initiation factor eIF4A. In this study, we demonstrated that a synthetic derivative of PatA, des-methyl des-amino PatA (DMDAPatA), blocked mRNA translation, reduced Mcl-1 protein and initiated apoptosis in CLL cells. This action was synergistic with the Bcl-2 antagonist ABT-199. However, avid binding to human plasma proteins limited DMDAPatA potency, precluding further development. To address this, we synthesized a new series of PatA analogs and identified three new leads with potent inhibition of translation. They exhibited less plasma protein binding and increased cytotoxic potency toward CLL cells than DMDAPatA, with greater selectivity towards CLL cells over normal lymphocytes. Computer modeling analysis correlated their structure–activity relationships and suggested that these compounds may act by stabilizing the closed conformation of eIF4A. Thus, these novel PatA analogs hold promise for application to cancers within the appropriate biological context, such as CLL.

UR - http://www.scopus.com/inward/record.url?scp=85060949419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060949419&partnerID=8YFLogxK

U2 - 10.1038/s41375-018-0364-x

DO - 10.1038/s41375-018-0364-x

M3 - Article

C2 - 30700841

AN - SCOPUS:85060949419

VL - 33

SP - 1663

EP - 1674

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -